FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386008046> ?p ?o ?g. }

• W4386008046 endingPage "19" @default.
• W4386008046 startingPage "18" @default.
• W4386008046 abstract "Diabetic macular edema (DME) is a signicant cause of visual impairment in individuals with diabetes. This prospective, randomized, comparative study aimed to assess the visual outcomes and complications associated with different doses (1mg, 2mg, and 4mg) of Intravitreal Triamcinolone Acetonide (IVTA) injection in patients with DME. A total of 75 patients were enrolled, and following clinical diagnosis, they were randomly assigned to receive one of the three IVTA doses. Visual acuity, intraocular pressure (IOP), cataract progression, and macular edema reduction were evaluated at various time points post-injection. The study found that visual acuity improvement was comparable between the 1mg and 2mg groups, showing 52% and 56% improvement, respectively. The 4mg group exhibited a slightly lower improvement rate of 40%. Fluorescein angiogram (FFA) results indicated that 68% of patients in the 2mg group showed improvement, while it was 60% in the 1mg group and 64% in the 4mg group. Optical coherence tomography (OCT) revealed a mean reduction in macular thickness of 59.28 micrometers in the 1mg group, 97.08 micrometers in the 2mg group, and 91.68 micrometers in the 4mg group. However, the study also observed signicant complications associated with the higher 4mg dose. Patients in the 4mg group experienced a more pronounced rise in IOP, which peaked at the end of the rst month post IVTA. Fortunately, IOP levels returned to normal by the end of three months with the help of topical antiglaucoma medications. Additionally, cataract progression was more prominent in the 4mg group compared to the 1mg and 2mg groups. In conclusion, this study suggests that administering a 4mg dose of IVTA does not yield signicantly better outcomes than a 2mg dose in terms of DME improvement. On the contrary, the higher dose is associated with a higher risk of complications, including elevated IOP and accelerated cataract formation in phakic patients. Thus, a careful consideration of the dose is crucial when using IVTA to treat diabetic macular edema." @default.
• W4386008046 created "2023-08-20" @default.
• W4386008046 creator A5000004817 @default.
• W4386008046 creator A5005092738 @default.
• W4386008046 creator A5010207535 @default.
• W4386008046 creator A5079594332 @default.
• W4386008046 date "2023-08-01" @default.
• W4386008046 modified "2023-10-14" @default.
• W4386008046 title "A COMPARATIVE STUDY OF EFFECTS OF INTRAVITREAL TRIAMCINOLONE ACETONIDE INJECTIONS OF DIFFERENT DOSES IN PATIENTS WITH DIABETIC MACULAR EDEMA" @default.
• W4386008046 doi "https://doi.org/10.36106/ijsr/1909954" @default.
• W4386008046 hasPublicationYear "2023" @default.
• W4386008046 type Work @default.
• W4386008046 citedByCount "0" @default.
• W4386008046 crossrefType "journal-article" @default.
• W4386008046 hasAuthorship W4386008046A5000004817 @default.
• W4386008046 hasAuthorship W4386008046A5005092738 @default.
• W4386008046 hasAuthorship W4386008046A5010207535 @default.
• W4386008046 hasAuthorship W4386008046A5079594332 @default.
• W4386008046 hasConcept C118487528 @default.
• W4386008046 hasConcept C134018914 @default.
• W4386008046 hasConcept C141071460 @default.
• W4386008046 hasConcept C2776251621 @default.
• W4386008046 hasConcept C2778257484 @default.
• W4386008046 hasConcept C2778903070 @default.
• W4386008046 hasConcept C2779829184 @default.
• W4386008046 hasConcept C2780347916 @default.
• W4386008046 hasConcept C2780886150 @default.
• W4386008046 hasConcept C2781092963 @default.
• W4386008046 hasConcept C2985127711 @default.
• W4386008046 hasConcept C555293320 @default.
• W4386008046 hasConcept C71924100 @default.
• W4386008046 hasConceptScore W4386008046C118487528 @default.
• W4386008046 hasConceptScore W4386008046C134018914 @default.
• W4386008046 hasConceptScore W4386008046C141071460 @default.
• W4386008046 hasConceptScore W4386008046C2776251621 @default.
• W4386008046 hasConceptScore W4386008046C2778257484 @default.
• W4386008046 hasConceptScore W4386008046C2778903070 @default.
• W4386008046 hasConceptScore W4386008046C2779829184 @default.
• W4386008046 hasConceptScore W4386008046C2780347916 @default.
• W4386008046 hasConceptScore W4386008046C2780886150 @default.
• W4386008046 hasConceptScore W4386008046C2781092963 @default.
• W4386008046 hasConceptScore W4386008046C2985127711 @default.
• W4386008046 hasConceptScore W4386008046C555293320 @default.
• W4386008046 hasConceptScore W4386008046C71924100 @default.
• W4386008046 hasLocation W43860080461 @default.
• W4386008046 hasOpenAccess W4386008046 @default.
• W4386008046 hasPrimaryLocation W43860080461 @default.
• W4386008046 hasRelatedWork W1175912066 @default.
• W4386008046 hasRelatedWork W1965989520 @default.
• W4386008046 hasRelatedWork W1991769640 @default.
• W4386008046 hasRelatedWork W1999877242 @default.
• W4386008046 hasRelatedWork W2001733471 @default.
• W4386008046 hasRelatedWork W2049217030 @default.
• W4386008046 hasRelatedWork W2232176731 @default.
• W4386008046 hasRelatedWork W2353997556 @default.
• W4386008046 hasRelatedWork W2367705216 @default.
• W4386008046 hasRelatedWork W2385736929 @default.
• W4386008046 isParatext "false" @default.
• W4386008046 isRetracted "false" @default.
• W4386008046 workType "article" @default.